TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Overview of attention for article published in Blood, November 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 5 news outlets

reddit: 1 Redditor

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Rx Road Map: Lisocabtagene Maraleucel in Follicular Lymphoma

Oncology Nursing News, 05 Jan 2026

For Which Patients With Follicular Lymphoma is Lisocabtagene Maraleucel Approved? On May 15, 2024, the FDA approved…

Lisocabtagene Maraleucel Expands the Therapeutic Landscape for Relapsed/Refractory Non-Hodgkin Lymphoma

Pharmacy Times, 27 Feb 2025

Treatment of non-Hodgkin lymphoma (NHL) has historically been centered around the administration of chemotherapy.

Breyanzi: BMS seeking to expand outreach of lymphoma therapy

BioProcess International, 22 Aug 2024

On Monday, Bristol Myers Squibb (BMS) announced the European Medicines Agency (EMA) validated the company’s Type II variation…

FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular Lymphoma and MCL

OncLive, 30 Jan 2024

Anne Kerber, MD The FDA has granted priority review to 2 supplemental biologics license applications (sBLAs) for lisocabtagene…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.